Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.
about
Knock-down of cathepsin D affects the retinal pigment epithelium, impairs swim-bladder ontogenesis and causes premature death in zebrafish.Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.N,N'-dinitrosopiperazine-mediated AGR2 is involved in metastasis of nasopharyngeal carcinomaCathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis.Clinical and Biological Significance of Cathepsin D Levels in Breast Cancer Cytosol in Women Over 70 years.Identification of C(6) -ceramide-interacting proteins in D6P2T Schwannoma cells.Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance.Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays.Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway.Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES).Neither creatinine nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents.
P2860
Q33958150-B97DC42C-DCBF-4E23-8E89-FBE1D5A936BCQ34433781-A0D4D889-7083-4F06-B1CE-7FF80B5BADEFQ35143700-28E13FC0-BBB4-47E1-B713-1EF6077CA732Q35840138-9F363F2C-5D01-463A-9823-F27E96BB8B43Q35887678-B645A5F5-CEF4-429B-AF09-63A211373050Q37218900-BB76B480-2182-4AAB-A328-F97D7C0925CAQ37334849-F63E3A49-F8A3-4F94-B061-73C8C229DE93Q37516412-15F95A6C-D822-4B08-9E64-82FBCE1478B6Q37808219-EA0ACCA9-5541-4488-A891-51D0B02E694CQ38298414-94CA5AF1-A9D9-4AF0-8A9D-F9654BC8F8C9Q39373589-DC354C6C-2611-4152-995B-BD78F45D3193Q42053453-9E5AF710-6CCD-47B6-AA2A-ABA026562C77Q42488465-DE11644A-4DF9-4FF1-AF72-10B66E59E9CDQ43877569-9D7312DD-2846-451F-924D-AB15A7188E42Q49097109-8A11F5F0-F242-488B-9847-8216F1562FA7
P2860
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Reevaluating cathepsin D as a ...... levels versus histopathology.
@ast
Reevaluating cathepsin D as a ...... levels versus histopathology.
@en
type
label
Reevaluating cathepsin D as a ...... levels versus histopathology.
@ast
Reevaluating cathepsin D as a ...... levels versus histopathology.
@en
prefLabel
Reevaluating cathepsin D as a ...... levels versus histopathology.
@ast
Reevaluating cathepsin D as a ...... levels versus histopathology.
@en
P2093
P2860
P356
P1476
Reevaluating cathepsin D as a ...... levels versus histopathology.
@en
P2093
Alfred Rademaker
Daniel E Abbott
David J Winchester
Jacqueline S Jeruss
Mary J C Hendrix
Naira V Margaryan
Nora Hansen
Seema Khan
Virginia Kaklamani
Zhila Khalkhali-Ellis
P2860
P356
10.4161/CBT.9.1.10378
P577
2010-01-15T00:00:00Z